[1000 osteoarthrosis patients in treatment with GGGs: an assessment of joint pain].
The analgesic activity of a chondroprotective agent--galactosamineglucuronoglycan sulphate (Condral) was evaluated in the course of an open investigation in a large number of outpatients attending the Istituto Emilio Bruzzone of Genoa or related Centres. Out of 1720 outpatients seen, 1000 were treated for 2 years with 800-1200 mg daily of GGG in one single administration (2-3 sachets or capsules of 400 mg) By the results obtained GGG was shown to have analgesic activity in a large number of cases. Tolerance of the treatment was good and no significant clinical side effects were ever observed.